Market Closed -
BME
16:35:26 26/04/2024 BST
5-day change
1st Jan Change
85
EUR
+0.35%
+7.05%
+41.20%
Sales 2024 *
824M
881M
70.58B
Sales 2025 *
906M
969M
77.62B
Capitalization
4.4B
4.71B
377B
Net income 2024 *
171M
183M
14.64B
Net income 2025 *
206M
220M
17.64B
EV / Sales 2024 *
5.3
x
Net cash position
2024
*
38.22M
40.87M
3.27B
Net cash position
2025
*
147M
157M
12.59B
EV / Sales 2025 *
4.7
x P/E ratio 2024 *
25.7
x
P/E ratio 2025 *
21.8
x
Employees
1,925
Yield 2024 *
1.32%
Yield 2025 *
1.52%
Free-Float
35.68%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment
04-02
MT
Rovi, Partners to Form Entity for Advanced Therapies R&D
03-12
MT
Rovi explores sale of unit that makes drugs for third parties
03-07
RE
Rovi Responds to Press Speculation Regarding Contract Development Business Deal
03-07
MT
Transcript : Laboratorios Farmaceuticos Rovi, S.A., 2023 Earnings Call, Feb 27, 2024
02-27
The Ibex-35 opts for caution as corporate results continue to trickle in.
02-27
RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
02-25
CI
US FDA finds control lapses at Moderna manufacturing plant
12-15
RE
Italy, Spain stocks hit peaks after over 20% rally in 2023
11-30
RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023
11-08
CI
Transcript : Laboratorios Farmaceuticos Rovi, S.A., H1 2023 Earnings Call, Jul 26, 2023
26/07/23
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
26/07/23
CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.
26/07/23
CI
Global markets live: Macy's, Salesforce, Dollar General, Nordstrom, Exxon...
01/06/23
Rovi denies being investigated for alleged public subsidies
01/06/23
RE
More news
Cinco valores que se deben tener muy en cuenta por técnico este viernes
04-26
Avis d'analystes du jour : Hermès, Sanofi, STMicroelectronics, BNP Paribas, Pluxee, Valeo, Nestlé...
04-26
OPINIONI DEGLI ANALISTI : Saipem, Italgas, Credito Emiliano, Salcef Group, Hermes International, Befesa, Sika, Italgas, Hermes, Repsol, Nestlé...
04-26
OPINIONES DE LOS ANALISTAS DEL DÍA : Rovi, Hermès, Repsol, Caixabank, Aedas Homes, STMicroelectronics, Ebro Foods, Sabadell, Iberdrola, Nestlé...
04-26
EN DIRECTO DESDE LOS MERCADOS: Acerinox, Aena, Mapfre, Repsol, Sacyr, Airbus, Anglo American, BHP, Microsoft, Alphabet...
04-26
More news 1 day +0.35%
1 week +7.05%
Current month +5.07%
1 month +6.05%
3 months +31.27%
6 months +72.27%
Current year +41.20%
More quotes
Managers
Title Age Since
Chief Executive Officer
-
31/12/93
Director of Finance/CFO
-
31/12/99
Chief Tech/Sci/R&D Officer
-
-
Members of the board
Title Age Since
Director/Board Member
-
31/12/94
Director of Finance/CFO
-
31/12/99
Chief Executive Officer
-
31/12/93
More insiders
Date
Price
Change
Volume
26/04/24
85
+0.35%
79,264
25/04/24
84.7
+6.41%
159,176
24/04/24
79.6
-1.06%
113,717
23/04/24
80.45
+1.26%
36,685
22/04/24
79.45
+0.06%
37,668
Delayed Quote
BME, April 26, 2024 at 04:35 pm
More quotes
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows:
- pharmaceutical products manufactured under contract (49%);
- prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.;
- diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals.
Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%).
Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
More about the company
Average target price
84.1
EUR
Spread / Average Target
-1.06%
Consensus
1st Jan change
Capi.
+41.20% 4.7B +25.83% 661B +27.00% 566B -6.76% 352B +20.34% 332B +3.00% 283B +13.09% 231B +5.46% 200B -9.61% 195B -6.26% 145B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1